Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
| Author | Imamovic, Denira |
| Author | Vranic, Semir |
| Available date | 2019-04-04T08:19:05Z |
| Publication Date | 2017-12-01 |
| Publication Name | Annals of translational medicine |
| Identifier | http://dx.doi.org/10.21037/atm.2017.09.32 |
| Citation | Imamovic D, Vranic S. Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4—a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors. Ann Transl Med 2017;5(23):467. doi: 10.21037/atm.2017.09.32 |
| ISSN | 2305-5839 |
| Abstract | CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors |
| Language | en |
| Publisher | AME Publishing Company |
| Subject | targeted therapy immune checkpoint inhibitors PD-L1 cancer |
| Type | Article |
| Issue Number | 23 |
| Volume Number | 5 |
Files in this item
This item appears in the following Collection(s)
-
Medicine Research [1509 items ]